Wondering why RYBELSUS® should be a go-to following metformin for your appropriate patients? In a head-to-head trial, the world's first and only oral GLP-1 RA delivered1:
RYBELSUS® delivered significant results across key secondary endpoints:
PIONEER 3 Study Design: RYBELSUS® vs Januvia®
Compare treatment of RYBELSUS® to Januvia® for A1C reductions in adult patients with type 2 diabetes
Patients were randomized to RYBELSUS® 3 mg (n=466), RYBELSUS® 7 mg (n=465), RYBELSUS® 14 mg (n=465), or Januvia® 100 mg (n=467), all once daily.
RYBELSUS® has wider commercial coverage than Januvia®a,b
aCalculated with NIAD market volume (previously GLP-1) to prepare for Rybelsus access calculations. Note: Data from VANTAGE Fingertip Formulary bridge/February 2021 Nomenclature, and Xponent PlanTrak using week ending 3/05/2021; only considers bridged volume; excludes cash and mail order data; based on full DCS/EDCS/OCS IC universe (targets and non-targets).
bNovo Nordisk defines access as covered when brand is available on formulary with or without restrictions. Coverage status and tier vary by plan and are subject to change. Please check directly with the health plan to confirm coverage for individual patients.